Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17603416 | 1.00 | IDH1 (0.56) | IDH1IDO1ABL1PDGFRBBCR | |
| SCHEMBL17603444 | 0.89 | IDH1 (0.69) | IDH1 | |
| SCHEMBL20559954 | 0.89 | IDH1 (0.69) | IDH1 | |
| SCHEMBL19991317 | 0.86 | IDH1 (0.57) | IDH1 | |
| SCHEMBL17603908 | 0.86 | IDH1 (0.57) | IDH1 | |
| SCHEMBL17603523 | 0.85 | IDH1 (0.50) | IDH1IDO1ABL1PDGFRBBCR | |
| SCHEMBL20560036 | 0.85 | IDH1 (0.50) | IDH1IDO1ABL1PDGFRBBCR | |
| SCHEMBL20559863 | 0.84 | IDH1 (0.49) | IDH1IDO1ABL1PDGFRBBCR | |
| SCHEMBL20559889 | 0.83 | IDH1 (0.48) | IDH1IDO1ABL1PDGFRBBCR | |
| SCHEMBL20559734 | 0.83 | IDH1 (0.52) | IDH1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194375-B1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | claimed |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | IDH1 1/4885IDO1 230/4885ABL1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.